Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 698

Sort by

Sort Order Select

Journal Articles

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Nitin Jain, Koji Sasaki, Rebecca Garris, Koichi Takahashi, Farhad Ravandi, Nicholas J. Short

Blood blood.2025030498.

https://doi.org/10.1182/blood.2025030498

Published: 2025

Includes: Supplemental data

Journal Articles

A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes

Manuel Maroun, Hagop Kantarjian, Nitin Jain, Omer Karrar, Fadi Haddad, Guilin Tang, Sanam Loghavi, Keyur Patel, Walid Macaron, Partow Kebriaei, Issa Khouri, Jairo Matthews, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Nicholas Short

Blood (2025) 146 (Supplement 1): 551.

https://doi.org/10.1182/blood-2025-551

Published: 2025

Journal Articles

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Nitin Jain, Fadi Haddad, Partow Kebriaei, Issa Khouri, Elizabeth Shpall, Richard Champlin, Jayastu Senapati, Eitan Kugler, Omer Karrar, Elias Maroun, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 549.

https://doi.org/10.1182/blood-2025-549

Published: 2025

Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood (2025) 146 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2025-3429

Published: 2025

Journal Articles

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Ghayas Issa, Hagop Kantarjian, Musa Yilmaz, Nicholas Short, Tapan Kadia, Georgina El Hajjar, Courtney DiNardo, Yesid Alvarado, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Michael Andreeff, Guillermo Garcia-Manero, Naval Daver

Blood (2025) 146 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2025-3428

Published: 2025

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sanam Loghavi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Jayastu Senapati, Wei-Ying Jen, Naveen Pemmaraju, Fnu Amritpal Singh, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2025-5179

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Ian Bouligny, Jayastu Senapati, Koji Sasaki, Ghayas Issa, Nicholas Short, Tapan Kadia, Rashmi Kanagal-Shamanna, Sanam Loghavi, Guilin Tang, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2025-5641

Published: 2025

Journal Articles

A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL

Eitan Kugler, Ken Furudate, Farhad Ravandi, Nitin Jain, Gautam Borthakur, Nicholas Short, Rebecca Garris, Hagop Kantarjian, Elias Jabbour, Koichi Takahashi

Blood (2025) 146 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2025-5151

Published: 2025

Journal Articles

Longitudinal clonotype tracking by next-generation sequencing (NGS) based T-cell receptor (TCR) rearrangement measurable residual disease (MRD) assay in frontline adult T-acute lymphoblastic leukemia (ALL)

Niranjan Khaire, Nicholas Short, Nitin Jain, Tapan Kadia, Gautam Borthakur, Jayastu Senapati, Abhishek Maiti, Alexandre Bazinet, Yesid Alvarado Valero, Hayley Balkin, Partow Kebriaei, Rebecca Garris, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 5150.

https://doi.org/10.1182/blood-2025-5150

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2025-3849

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner, Francisco Vega, Deepa Sampath, Alessandra Ferrajoli, Kelly Chien, Elias Jabbour, Danielle Hammond, Nicholas Short, Koichi Takahashi, Nitin Jain, Jan Burger, Gautam Borthakur, William Wierda, Chitra Hosing, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2025-3653

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL

Longitudinal clonotype tracking by next-generation sequencing (NGS) based T-cell receptor (TCR) rearrangement measurable residual disease (MRD) assay in frontline adult T-acute lymphoblastic leukemia (ALL)

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only